Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD4 | Q53EL6 | 8/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | TUBAL3 | A6NHL2 | 2/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.33 |
| ▸ | TUBA8 | Q9NY65 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9992398 | 0.94 | PDCD4 (0.36) | PDCD4TUBAL3TUBA3CTUBA1BTUBA4A | |
| SCHEMBL9991171 | 0.84 | PDCD4 (0.37) | PDCD4DAGLAXPO1 | |
| SCHEMBL16431359 | 0.81 | PDCD4 (0.38) | PDCD4DAGLATRPA1NR4A2XPO1 | |
| SCHEMBL38651019 | 0.81 | PDCD4 (0.38) | PDCD4DAGLATRPA1NR4A2XPO1 | |
| SCHEMBL1895638 | 0.76 | PDCD4 (0.43) | PDCD4 | |
| SCHEMBL2315807 | 0.76 | PDCD4 (0.43) | PDCD4 | |
| SCHEMBL31264316 | 0.76 | NLRP3 (0.34) | PDCD4 | |
| SCHEMBL3663425 | 0.76 | PDCD4 (0.43) | PDCD4 | |
| SCHEMBL31264317 | 0.76 | NLRP3 (0.34) | PDCD4 | |
| SCHEMBL8985124 | 0.76 | PDCD4 (0.43) | PDCD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8177896-B2 | Antifouling furan-2-one derivatives | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2012-05-15 | — | — | US | disclosed |
| US-8177896-B2 | Antifouling furan-2-one derivatives | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2012-05-15 | — | — | US | disclosed |
| US-20110185944-A1 | ANTIFOULING FURAN-2-ONE DERIVATIVES | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2011-08-04 | — | — | US | disclosed |
| US-20110185944-A1 | ANTIFOULING FURAN-2-ONE DERIVATIVES | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2011-08-04 | — | — | US | disclosed |
| WO-2010009632-A1 | ANTIFOULING FURAN-2-ONE DERIVATIVES | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110185944-A1 | ANTIFOULING FURAN-2-ONE DERIVATIVES | FSCN1, PFAS, PFN1 | PDCD4 3370/4885DAGLA 2244/4885TUBAL3 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.